Medical
CAR-T Cell Therapy for Mesothelioma: 72% Response Rate in MSKCC Phase I Trial and 5 Active 2026 Studies
David Foster
April 6, 2026
Mesothelin-targeted CAR-T therapy reached a 72% response rate when combined with pembrolizumab at MSKCC. Learn how engineered T cells are changing mesothelioma treatment in 2026.
12 min read 8 FAQs
Read